Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
AS

NASDAQ · ASMB

Assembly Biosciences, Inc.

Healthcare · Biotechnology

$25.48

Down-$0.63 (-2.41%)

Updated Sep 17, 2026, 6:40 AM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
256.95M
P/E ratio
-5.93
Dividend yield
0.00%
52-week range
$21.80 – $37.01
Volume
348.79K
Avg. volume
121.21K

Price performance

ASMB price history

1M range · 20 trading sessions · Daily adjusted prices

ASMB closed at $25.48 after 20 trading sessions, down 24.70% for the selected period.

Last close
$25.48
Period change
-24.70%
Period low
$25.48
Period high
$36.72
Daily close
View OHLC price history
ASMB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$26.11$26.6926$25.13$25.48348.79K
Sep 15, 2026$29.00$29.655$25.31$26.11588.85K
Sep 14, 2026$30.31$30.48$28.79$28.96290.47K
Sep 11, 2026$30.83$31.72$29.68$29.80258.95K
Sep 10, 2026$32.56$32.69$30.34$30.46348.62K
Sep 9, 2026$35.64$35.925$32.73$32.87724.82K
Sep 8, 2026$36.16$36.68$35.145$35.28227.77K
Sep 4, 2026$35.68$36.765$35.485$36.60156.45K
Sep 3, 2026$36.80$36.80$35.54$36.13224.98K
Sep 2, 2026$35.48$37.01$34.86$36.72267.54K
Sep 1, 2026$34.12$35.33$33.43$35.18301.1K
Aug 31, 2026$33.80$34.30$32.92$33.63235.97K
Aug 28, 2026$34.58$34.58$33.29$34.07250.03K
Aug 27, 2026$35.32$35.895$34.75$34.80192.12K
Aug 26, 2026$35.38$36.13$35.00$35.42171.49K
Aug 25, 2026$36.00$37.00$35.19$35.33553.78K
Aug 24, 2026$34.38$36.12$33.7501$35.28384.17K
Aug 21, 2026$33.86$35.62$33.86$34.38341.54K
Aug 20, 2026$33.54$34.00$32.90$33.53215.02K
Aug 19, 2026$32.88$34.57$32.6426$33.84384.57K

Latest ASMB news

The latest Smart Investors Daily articles mentioning ASMB.

Stock researchCompany · Overview

ASMB research

Overview

Company profile and research snapshot.

Company profile

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$39.00
Implied upside
—
Analysts
11
ASMB recent ratings
DateFirmRatingTarget
Sep 1, 2026MizuhoOutperform—
Sep 1, 2026UBSBuy—
Aug 18, 2026HC Wainwright & Co.Buy—
Jun 15, 2026MizuhoOutperform—
May 28, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026. A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be

Yahoo · Sep 8, 2026

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 – SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced it

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By